Further, XPO1 inhibition decreased cell fitness in other MYC-driven tumors including human P493-6 Burkitt lymphoma-like, a murine MYC-induced T-cell leukemia and a murine IgH-MYC B-cell lymphoma cell line (Supplementary Fig. 9). This evidence concerns the gene XPO1 and B-cell non-Hodgkin lymphoma.